How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about efgartigimod

Marketing authorisation indication

2.1

Efgartigimod (Vyvgart, Argenx) is indicated for 'the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins'.

Dosage in the marketing authorisation

Price

2.3

The list price of efgartigimod is £15,307.47 for a pre-filled 5-ml syringe containing 1,000 mg of efgartigimod (200 mg per ml; excluding VAT, sourced from company submission).

2.4

The company has a commercial arrangement. This makes efgartigimod available to the NHS with a discount and it would have also applied to this indication if efgartigimod had been recommended. The size of the discount is commercial in confidence.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Argenx will be included here when guidance is published.